Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

Fig. 5

Enzymatic assay test for PARP inhibition by measuring the incorporation of biotinylated poly(ADP-ribose) onto histone proteins by the PARP enzyme. This allowed the determination of the IC50 value of our new PARP-DNA combi-molecule, EG22. The Trevigen HT Universal Colorimetric PARP assay kit with histone-coated strip wells was used and dose response curves analyzed with the Graphpad Prism software. The results showed that EG22 was capable of inducing a dose-dependent inhibition of PARP with IC50 = 0.1 μM

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us